The Nordic EMBL Partnership is a major strategic player in Europe’s molecular understanding of disease mechanisms, thanks to its complementary research expertise, outstanding research infrastructures and industry collaborations. The Nordic EMBL Partnership was initiated as a collaboration in 2008 between EMBL and the Laboratory for Molecular Infection Medicine Sweden (MIMS) at Umeå University, the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki and the Centre for Molecular Medicine Norway (NCMM) at the University of Oslo. In 2013 the Nordic EMBL Partnership was extended when the Danish Research Institute of Translational Neuroscience (DANDRITE) at Aarhus University in Denmark became the Danish node. The Partnership now consists of four Nordic research centres, with around 50 Group Leaders and 500 researchers and staff. The individual nodes of the Nordic EMBL Partnership for Molecular Medicine contribute the following complementary strengths thereby extending the EMBL's recognized research expertise within cell biology and biophysics, developmental biology, genome biology and bioinformatics and structural biology: DANDRITE: Molecular and translational neuroscience FIMM: Human genomics, systems and precision medicine MIMS: Microbial pathogenicity and molecular infection medicine NCMM: Molecular mechanism of disease The Partnership strives to retain and attract the very best international research talent, through providing an excellent research environment for young, talented researchers with the aim that they will continue their scientific careers in one of the Nordic countries. All nodes are nationally funded and further supported by the EMBL, through access to scientific infrastructure, services and training. Each Nordic partner has adopted the EMBL model for international recruitment, staff turnover and scientific reviews. The coordination between the Nordic nodes and EMBL is overseen by two representatives from each node.